Peter Wilkinson - Laboratory Senior Vice President, Chief Accounting Officer
| LH Stock | USD 207.97 4.90 2.41% |
President
Mr. Peter Wilkinson is appointed as Senior Vice President, Chief Accounting Officer of the company effective April 1, 2019. Mr. Wilkinson currently serves in the role of LabCorporations Senior Vice President, Accounting since January 2019. Prior to that, Mr. Wilkinson served as Executive Vice President and Chief Financial Officer of Syneos Health, Inc.s clinical division, a biopharmaceuticals services organization, from August 2017 to July 2018 and as Senior Vice President and Chief Accounting Officer of INC Research Holdings, Inc., a publicly traded predecessor to Syneos Health, from February 2016 to August 2017. Mr. Wilkinson also previously served as Senior Vice President in the INC Research Finance Department from April 2014 to February 2016. Prior to his position with INC Research, Mr. Wilkinson worked as a selfemployed Financial Consultant following an earlier career as a Financial and Accounting Officer at Pharmaceutical Product Development, LLC, a clinical research organization. since 2019.
| Age | 52 |
| Tenure | 5 years |
| Address | 358 South Main Street, Burlington, NC, United States, 27215 |
| Phone | 336 229 1127 |
| Web | https://www.labcorp.com |
Peter Wilkinson Latest Insider Activity
Tracking and analyzing the buying and selling activities of Peter Wilkinson against Laboratory stock is an integral part of due diligence when investing in Laboratory. Peter Wilkinson insider activity provides valuable insight into whether Laboratory is net buyers or sellers over its current business cycle. Note, Laboratory insiders must abide by specific rules, including filing SEC forms every time they buy or sell Laboratory'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Peter Wilkinson over two months ago Payment of tradable shares by Peter Wilkinson of Laboratory subject to Rule 16b-3 | ||
Peter Wilkinson over two months ago Exercise or conversion by Peter Wilkinson of 131 shares of Laboratory subject to Rule 16b-3 | ||
Peter Wilkinson over three months ago Sale by Peter Wilkinson of 1384 shares of Laboratory | ||
Peter Wilkinson over a year ago Payment of tradable shares by Peter Wilkinson of Laboratory subject to Rule 16b-3 |
Laboratory Management Efficiency
The company has Return on Asset (ROA) of 0.0377 % which means that for every $100 of assets, it generated a profit of $0.0377. This is way below average. Likewise, it shows a return on total equity (ROE) of 0.0423 %, which means that it produced $0.0423 on every 100 dollars invested by current stockholders. Laboratory's management efficiency ratios could be used to measure how well Laboratory manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to 0.05. The current Return On Capital Employed is estimated to decrease to 0.08. As of now, Laboratory's Total Current Assets are increasing as compared to previous years. The Laboratory's current Other Assets is estimated to increase to about 531.7 M, while Non Currrent Assets Other are projected to decrease to under 270.8 M.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Allison Bebo | Hologic | 49 | |
| Cynthia Zipperle | Humana Inc | 58 | |
| Elizabeth Rae | Waters | 60 | |
| Susan Diamond | Humana Inc | 50 | |
| Bethanie Stein | Humana Inc | N/A | |
| Heidi Margulis | Humana Inc | 63 | |
| John III | Humana Inc | N/A | |
| James Davis | Quest Diagnostics Incorporated | 61 | |
| Marc Miller | Universal Health Services | 53 | |
| Claus Egstrand | Hologic | 52 | |
| Jon Cohen | Quest Diagnostics Incorporated | 64 | |
| Jan Verstreken | Hologic | 56 | |
| Rohit Khanna | Waters | 58 | |
| Marvin Pember | Universal Health Services | 66 | |
| Steve Filton | Universal Health Services | 66 | |
| Roy Beveridge | Humana Inc | 59 | |
| Christopher Todoroff | Humana Inc | 54 | |
| Thomas Liston | Humana Inc | 51 | |
| Michael Deppe | Quest Diagnostics Incorporated | 57 | |
| James MBA | Humana Inc | 53 | |
| Tim McClain | Humana Inc | 64 | |
Management Performance
| Return On Equity | 0.0423 | ||||
| Return On Asset | 0.0377 |
Laboratory Leadership Team
Elected by the shareholders, the Laboratory's board of directors comprises two types of representatives: Laboratory inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Laboratory. The board's role is to monitor Laboratory's management team and ensure that shareholders' interests are well served. Laboratory's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Laboratory's outside directors are responsible for providing unbiased perspectives on the board's policies.
| William Klitgaard, President- Enlighten Health | ||
| Paul Surdez, IR Contact Officer | ||
| Deborah Tanner, CEO - Covance Drug Development (Covance) | ||
| Stephen Anderson, Vice President Investor Relations | ||
| Sanders Williams, Independent Director | ||
| JD MD, President EVP | ||
| Amy Summy, Executive Vice President Chief Marketing Officer | ||
| Mark Schroeder, Executive Vice President and Presidentident of Diagnostics Laboratory Operations and Global Supply Chain | ||
| Robert Pringle, Senior Treasurer | ||
| Peter Wilkinson, Senior Vice President, Chief Accounting Officer | ||
| Lisa Uthgenannt, Chief Human Resource Officer, Senior Vice President | ||
| Brian Caveney, Executive Vice President, President, Diagnostics and Chief Medical Officer | ||
| D Gilliland, Independent Director | ||
| Gary Huff, CEO, LabCorp Diagnostics | ||
| JeanLuc Belingard, Independent Director | ||
| Clarissa Willett, IR Contact Officer | ||
| Peter Neupert, Lead Independent Director | ||
| Robert Williams, Independent Director | ||
| Megan MPH, Executive Officer | ||
| Chas Cook, VP Relations | ||
| Garheng Kong, Independent Director | ||
| Gary Gilliland, Independent Director | ||
| David King, Chairman of the Board, President, Chief Executive Officer | ||
| Adam Schechter, Chairman of the Board, President, Chief Executive Officer | ||
| Mark Brecher, Senior Vice President Chief Medical Officer | ||
| Samuel Eberts, Senior Vice President Chief Compliance Officer, Secretary, Chief Legal Officer | ||
| Sandra Vaart, Executive Vice President, Chief Legal Officer, Chief Compliance Officer and Secretary | ||
| Edward Dodson, Chief Accounting Officer and Sr. VP | ||
| Robert Mittelstaedt, Lead Independent Director | ||
| Anita Graham, Executive Officer | ||
| Glenn Eisenberg, Chief Financial Officer, Executive Vice President | ||
| Lance Berberian, Executive Vice President, Chief Technology Officer, Chief Information Officer | ||
| Judith Seltz, Chief Human Resource Officer, Executive Vice President | ||
| Michelle Abelson, Laboratory Operations | ||
| Jonathan DiVincenzo, Executive International | ||
| John Ratliff, Chief Executive Officer - Covance Drug Development | ||
| Kerrii Anderson, Independent Director | ||
| Paul MD, Ex Devel | ||
| Marcia Eisenberg, Chief VP | ||
| John Treadwell, Vice Initiatives | ||
| Kathryn Wengel, Independent Director | ||
| Paul Kirchgraber, Executive Vice President and Chief Executive Officer - Covance Drug Development | ||
| James Boyle, Executive VP and CEO of Labcorp Diagnostics | ||
| Richelle Parham, Independent Director | ||
| Jeffrey Davis, Independent Director | ||
| Christin ODonnell, Vice Relations | ||
| Deborah SesokPizzini, SVP Officer | ||
| Scott Frommer, Vice President - Investor Relations | ||
| MPH MD, Pres VP |
Laboratory Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Laboratory a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0423 | ||||
| Return On Asset | 0.0377 | ||||
| Profit Margin | 0.03 % | ||||
| Operating Margin | 0.07 % | ||||
| Current Valuation | 22.51 B | ||||
| Shares Outstanding | 84.13 M | ||||
| Shares Owned By Insiders | 0.34 % | ||||
| Shares Owned By Institutions | 98.96 % | ||||
| Number Of Shares Shorted | 1.92 M | ||||
| Price To Earning | 12.69 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Laboratory of. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in rate. Note that the Laboratory information on this page should be used as a complementary analysis to other Laboratory's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Complementary Tools for Laboratory Stock analysis
When running Laboratory's price analysis, check to measure Laboratory's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Laboratory is operating at the current time. Most of Laboratory's value examination focuses on studying past and present price action to predict the probability of Laboratory's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Laboratory's price. Additionally, you may evaluate how the addition of Laboratory to your portfolios can decrease your overall portfolio volatility.
| Transaction History View history of all your transactions and understand their impact on performance | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences |
Is Laboratory's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Laboratory. If investors know Laboratory will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Laboratory listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.46) | Dividend Share 2.88 | Earnings Share 4.33 | Revenue Per Share 139.628 | Quarterly Revenue Growth 0.035 |
The market value of Laboratory is measured differently than its book value, which is the value of Laboratory that is recorded on the company's balance sheet. Investors also form their own opinion of Laboratory's value that differs from its market value or its book value, called intrinsic value, which is Laboratory's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Laboratory's market value can be influenced by many factors that don't directly affect Laboratory's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Laboratory's value and its price as these two are different measures arrived at by different means. Investors typically determine if Laboratory is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Laboratory's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.